The number of treatment courses for Upadacitinib needs to be determined based on the type of indication, treatment response, and individual tolerance. Typically, the efficacy evaluation cycle is 3-6 months, and the specific treatment plan needs to be dynamically adjusted by rheumatologists or dermatologists.

1. Treatment standards for different indications

(1) Rheumatoid arthritis: Initial treatment is recommended for at least 3 courses (9-12 months), followed by standard treatment and maintenance treatment. Most patients require continuous medication.

(2) Atopic dermatitis: Moderate to severe patients typically require 2-4 courses of treatment (6-12 months), and 75% of patients may consider reducing their dosage after achieving EASI-75 response in week 16.

2. Basis for adjusting treatment courses

(1) Efficacy indicators: ACR50 response rate or SCORAD score should be evaluated for each course of treatment, and those who fail to meet the standards should consider increasing the course of treatment or replacing biological agents.

(2) Safety monitoring: In the event of severe infections, venous thrombosis, or other adverse reactions, the current course of treatment may be terminated and subsequent plans adjusted.

3 Differences in treatment courses for special populations

(1) Elderly patients: It is recommended to extend the interval between treatment courses and evaluate the necessity of medication every 6 months.

(2) For patients with liver and kidney dysfunction: it may be necessary to reduce the dosage of a single course of medication, but the total number of courses is usually unchanged.